Exhibit 10.1
BRIDGE LOAN
AGREEMENT
THIS BRIDGE LOAN
AGREEMENT , dated as of
August 18, 2005, is entered into by and between WORLD HEALTH
ALTERNATIVES, INC. , a Florida corporation (the
“Company”), and each individual or entity named on a
signature page hereto (as used herein, each such signatory is
referred to as the “Lender” or a “Lender”)
(each agreement with a Lender being deemed a separate and
independent agreement between the Company and such Lender, except
that each Lender acknowledges and consents to the rights granted to
each other Lender [each, an “Other Lender”] under such
agreement and the Transaction Agreements, as defined below,
referred to therein).
W I T N E S S E T
H:
WHEREAS , the Company and each of the Lenders are
executing and delivering this Agreement in accordance with and in
reliance upon the exemption from securities registration for offers
and sales to accredited investors afforded, inter
alia , by Rule 506 under Regulation D (“Regulation
D”) as promulgated by the United States Securities and
Exchange Commission (the “SEC”) under the Securities
Act of 1933, as amended (the “1933 Act”), and/or
Section 4(2) of the 1933 Act; and
WHEREAS , each Lender wishes to lend funds to the
Company, subject to and upon the terms and conditions of this
Agreement and acceptance of this Agreement by the Company, the
repayment of which will be represented by a Promissory Note of the
Company (each, a “Note”), on the terms and conditions
referred to herein; and
WHEREAS, in connection with the loan to be made by each
Lender, the Company has agreed to issue the Issued Shares (as those
terms are defined below) to the Lender; and
NOW THEREFORE
, in consideration of the premises
and the mutual covenants contained herein and other good and
valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties agree as follows:
1. AGREEMENT TO PURCHASE;
PURCHASE PRICE.
a. Purchase.
(i) Subject to the terms and
conditions of this Agreement and the other Transaction Agreements,
each Lender hereby agrees to loan to the Company the principal
amount specified on the Lender’s signature page hereof (the
“Loan Amount”). The aggregate Loan Amount of all
Lenders shall be $4,000,000.00 (the “Aggregate Loan
Amount”).
(ii) The obligation to repay the
loan from the Lender shall be evidenced by the Company’s
issuance of the Note, which shall be in the form of Annex I
annexed hereto, and which the Company shall execute following the
execution of this Bridge Loan Agreement by all parties.
(iii) In consideration for this
loan, the Company agrees to lower the conversion price on the
Convertible Debentures issued on May 17, 2005 in the aggregate
amount of $22,037,828.93 from $3.00 to $1.25.
(iv) The loan to be made by the
Lender and the issuance of the Note to the Lender and the other
transactions contemplated hereby are sometimes referred to herein
and in the other Transaction Agreements as the purchase and sale of
the Securities (as defined below), and are referred to collectively
as the “Transactions.”
b. Certain
Definitions. As used
herein, each of the following terms has the meaning set forth
below, unless the context otherwise requires:
“Affiliate” means, with
respect to a specific Person referred to in the relevant provision,
another Person who or which controls or is controlled by or is
under common control with such specified Person.
“Certificates” means the
Note each duly executed by the Company and issued on the Closing
Date in the name of the Lender.
“Closing Date” means the
date of the closing of the Transactions, as provided
herein.
“Company Control Person”
means each director, executive officer, promoter, and such other
Persons as may be deemed in control of the Company pursuant to Rule
405 under the 1933 Act or Section 20 of the 1934 Act (as defined
below).
“Holder” means the
Person holding the relevant Securities at the relevant
time.
“Last Audited Date”
means December 31, 2004.
“Lender Control Person”
means each director, executive officer, promoter, and such other
Persons as may be deemed in control of the Lender pursuant to Rule
405 under the 1933 Act or Section 20 of the 1934 Act.
“Lender’s Allocable
Share” means the fraction, of which the numerator is the
Lender’s Loan Amount and the denominator is the Aggregate
Loan Amount.
“Material Adverse
Effect” means an event or combination of events, which
individually or in the aggregate, would reasonably be expected to
(w) adversely affect the legality, validity or enforceability of
the Securities or any of the Transaction Agreements, (x) have or
result in a material adverse effect on the results of operations,
assets, prospects, or condition (financial or otherwise) of the
Company and its subsidiaries, taken as a whole, (y) adversely
impair the Company’s ability to perform fully on a timely
basis its obligations under any of the Transaction Agreements or
the transactions contemplated thereby, or (z) materially and
adversely affect the value of the rights granted to the Lender in
the Transaction Agreements.
2
“Person” means any
living person or any entity, such as, but not necessarily limited
to, a corporation, partnership or trust.
“Principal Trading
Market” means the Over the Counter Bulletin Board or such
other market on which the Common Stock is principally traded at the
relevant time.
“Registrable Securities”
means the shares issued to the Lenders.
“Registration Rights
Provisions” means the piggy-back registration rights
contemplated by the terms of this Agreement, including, but not
necessarily limited to, Section 4(g) hereof, and of the other
Transaction Agreements.
“Registration Statement”
means an effective registration statement covering the Registrable
Securities.
“Securities” means the
Note, and the Shares.
“Shares” means the
shares issued to the Lenders.
“State of Incorporation”
means Florida.
“Trading Day” means any
day during which the Principal Trading Market shall be open for
business.
“Transfer Agent” means,
at any time, the transfer agent for the Company’s Common
Stock.
“Transaction Agreements”
means this Bridge Loan Agreement, and the Note, and includes all
ancillary documents referred to in those agreements.
c. Form of Payment; Delivery of
Certificates.
(i) The Lender shall pay the Loan
Amount by delivering immediately available good funds in United
States Dollars to the Escrow Agent no later than the date prior to
the Closing Date.
(ii) No later than the Closing Date,
but in any event promptly following payment by the Lender to the
Company of the Loan Amount, the Company shall deliver the
Certificates, each duly executed on behalf of the Company and
issued in the name of the Lender, to the Lender.
3
d. Method of Payment.
Payment of the Loan Amount shall be
made by wire transfer of funds to:
|
|
|
|
|
Bank:
|
|
PNC Bank
NA
|
|
|
|
|
Branch Address:
|
|
Miracle Mile
Banking Center
|
|
|
|
|
|
|
Monroevile, PA
15146
|
|
|
|
|
Account
Name:
|
|
World Health
Alternative, Inc.
|
|
|
|
|
Account
No.:
|
|
1011317753
|
|
|
|
|
ABA
No.:
|
|
043000096
|
2. LENDER REPRESENTATIONS,
WARRANTIES, ETC.; ACCESS TO INFORMATION; INDEPENDENT
INVESTIGATION.
The Lender represents and warrants
to, and covenants and agrees with, the Company as
follows:
a. Without limiting Lender’s right to sell
the Securities pursuant to an effective registration statement or
otherwise in compliance with the 1933 Act, the Lender is purchasing
the Securities for its own account for investment only and not with
a view towards the public sale or distribution thereof and not with
a view to or for sale in connection with any distribution
thereof.
b. The Lender is (i) an “accredited
investor” as that term is defined in Rule 501 of the General
Rules and Regulations under the 1933 Act by reason of Rule
501(a)(3), (ii) experienced in making investments of the kind
described in this Agreement and the related documents, (iii) able,
by reason of the business and financial experience of its officers
(if an entity) and professional advisors (who are not affiliated
with or compensated in any way by the Company or any of its
Affiliates or selling agents), to protect its own interests in
connection with the transactions described in this Agreement, and
the related documents, and to evaluate the merits and risks of an
investment in the Securities, and (iv) able to afford the entire
loss of its investment in the Securities.
c. All subsequent offers and sales of the
Securities by the Lender shall be made pursuant to registration of
the relevant Securities under the 1933 Act or pursuant to an
exemption from registration.
4
d. The Lender understands that the Securities are
being offered and sold to it in reliance on specific exemptions
from the registration requirements of the 1933 Act and state
securities laws and that the Company is relying upon the truth and
accuracy of, and the Lender’s compliance with, the
representations, warranties, agreements, acknowledgments and
understandings of the Lender set forth herein in order to determine
the availability of such exemptions and the eligibility of the
Lender to acquire the Securities.
e. The Lender and its advisors, if any, have been
furnished with or have been given access to all materials relating
to the business, finances and operations of the Company and
materials relating to the offer and sale of the Securities which
have been requested by the Lender, including those set forth on in
any annex attached hereto. The Lender and its advisors, if any,
have been afforded the opportunity to ask questions of the Company
and its management and have received complete and satisfactory
answers to any such inquiries. Without limiting the generality of
the foregoing, the Lender has also had the opportunity to obtain
and to review the Company’s filings on EDGAR.
f. The Lender understands that its investment in
the Securities involves a high degree of risk.
g. The Lender hereby represents that, in connection
with its purchase of the Securities, it has not relied on any
statement or representation by the Company or any finders or any of
their respective officers, directors and employees or any of their
respective attorneys or agents.
h. The Lender understands that no United States
federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of
the Securities.
i. This Agreement and the other Transaction
Agreements to which the Lender is a party, and the transactions
contemplated thereby, have been duly and validly authorized,
executed and delivered on behalf of the Lender and are valid and
binding agreements of the Lender enforceable in accordance with
their respective terms, subject as to enforceability to general
principles of equity and to bankruptcy, insolvency, moratorium and
other similar laws affecting the enforcement of creditors’
rights generally.
3. COMPANY REPRESENTATIONS,
ETC. The Company
represents and warrants to the Lender as of the date hereof and as
of the Closing Date that, except as otherwise provided in Annex
V hereto or in the Company’s SEC Documents:
a. Rights of Others Affecting the
Transactions. There are
no preemptive rights of any shareholder of the Company, as such, to
acquire the Notes. No party other than a Lender or an Other Lender
has a currently exercisable right of first refusal, which would be
applicable to any or all of the transactions contemplated by the
Transaction Agreements.
5
b. Status.
The Company is a corporation duly
organized, validly existing and in good standing under the laws of
the State of Incorporation and has the requisite corporate power to
own its properties and to carry on its business as now being
conducted. The Company is duly qualified as a foreign corporation
to do business and is in good standing in each jurisdiction where
the nature of the business conducted or property owned by it makes
such qualification necessary, other than those jurisdictions in
which the failure to so qualify would not have or result in a
Material Adverse Effect. The Company has registered its stock and
is obligated to file reports pursuant to Section 12 or Section
15(d) of the Securities and Exchange Act of 1934, as amended (the
A1934 Act”). The Common Stock is quoted on the Principal
Trading Market. The Company has received no notice, either oral or
written, with respect to the continued eligibility of the Common
Stock for such quotation on the Principal Trading Market, and the
Company has maintained all requirements on its part for the
continuation of such quotation.
c. Authorized
Shares.
(i) The authorized capital stock of
the Company consists of 200,000,000 shares of Common Stock, $.0001
par value per share, of which approximately 79,000,000 are
outstanding as of the date hereto.
(ii) As of the date hereof and as of
the Closing Date, (1) there are no outstanding securities which are
convertible into shares of Common Stock, whether such conversion is
currently exercisable or exercisable only upon some future date or
the occurrence of some event in the future and (2) the Company has
not issued any warrants or other rights to acquire shares of the
Common Stock other than those referred to in the Company’s
SEC Documents. If any such securities are listed on Annex VI, the
number or amount of each such outstanding convertible security and
the conversion terms thereof or of each such warrant or other right
and the terms of its exercise are set forth in said Annex
VI.
(iii) All issued and outstanding
shares of Common Stock have been duly authorized and validly issued
and are fully paid and non-assessable. The Company has sufficient
authorized and unissued shares of Common Stock as may be necessary
to effect the issuance of the Shares on the Closing
Date.
(iv) As of the Closing Date, the
Shares shall have been duly authorized by all necessary corporate
action on the part of the Company, and, when issued on the Closing
Date or pursuant to other relevant provisions of the Transaction
Agreements, in each case in accordance with their respective terms,
will be duly and validly issued, fully paid and non-assessable and
will not subject the Holder thereof to personal liability by reason
of being such Holder.
d. Transaction Agreements and
Stock. This Agreement and
each of the other Transaction Agreements, and the transactions
contemplated thereby, have been duly and validly
6
authorized by the Company, this Agreement has
been duly executed and delivered by the Company and this Agreement
is, and the Notes, and each of the other Transaction Agreements,
when executed and delivered by the Company, will be, valid and
binding agreements of the Company enforceable in accordance with
their respective terms, subject as to enforceability to general
principles of equity and to bankruptcy, insolvency, moratorium, and
other similar laws affecting the enforcement of creditors’
rights generally.
e. Non-contravention.
The execution and delivery of this
Agreement and each of the other Transaction Agreements by the
Company, the issuance of the Securities, and the consummation by
the Company of the other transactions contemplated by this
Agreement, the Notes, the Warrants and the other Transaction
Agreements do not and will not conflict with or result in a breach
by the Company of any of the terms or provisions of, or constitute
a default under (i) the certificate of incorporation or by-laws of
the Company, each as currently in effect, (ii) any indenture,
mortgage, deed of trust, or other material agreement or instrument
to which the Company is a party or by which it or any of its
properties or assets are bound, including any listing agreement for
the Common Stock except as herein set forth, or (iii) to its
knowledge, any existing applicable law, rule, or regulation or any
applicable decree, judgment, or order of any court, United States
federal or state regulatory body, administrative agency, or other
governmental body having jurisdiction over the Company or any of
its properties or assets, except such conflict, breach or default
which would not have or result in a Material Adverse
Effect.
f. Approvals.
No authorization, approval or
consent of any court, governmental body, regulatory agency,
self-regulatory organization, or stock exchange or market or the
shareholders of the Company is required to be obtained by the
Company for the issuance and sale of the Securities to the Lender
as contemplated by this Agreement, except such authorizations,
approvals and consents that have been obtained.
g. Filings.
None of the Company’s SEC
Documents contained, at the time they were filed, any untrue
statement of a material fact or omitted to state any material fact
required to be stated therein or necessary to make the statements
made therein in light of the circumstances under which they were
made, not misleading. Since September 1, 2003, the Company has
timely filed all requisite forms, reports and exhibits thereto
required to be filed by the Company with the SEC.
h. Absence of Certain
Changes. Since the Last
Audited Date, there has been no material adverse change and no
Material Adverse Effect, except as disclosed in the Company’s
SEC Documents. Since the Last Audited Date, except as provided in
the Company’s SEC Documents, the Company has not (i) incurred
or become subject to any material liabilities (absolute or
contingent) except liabilities incurred in the ordinary course of
business consistent with past practices; (ii) discharged or
satisfied any material lien or encumbrance or paid any material
obligation or liability (absolute or contingent), other than
current liabilities paid in the ordinary course of business
consistent with past practices; (iii) declared or made any payment
or distribution of cash or other property to shareholders with
respect to its capital stock, or purchased or redeemed, or made
any
7
agreements to purchase or redeem, any shares of
its capital stock; (iv) sold, assigned or transferred any other
tangible assets, or canceled any debts owed to the Company by any
third party or claims of the Company against any third party,
except in the ordinary course of business consistent with past
practices; (v) waived any rights of material value, whether or not
in the ordinary course of business, or suffered the loss of any
material amount of existing business; (vi) made any increases in
employee compensation, except in the ordinary course of business
consistent with past practices; or (vii) experienced any material
problems with labor or management in connection with the terms and
conditions of their employment.
i. Full Disclosure.
To the best of the Company’s
knowledge, there is no fact known to the Company (other than
general economic conditions known to the public generally or as
disclosed in the Company’s SEC Documents) that has not been
disclosed in writing to the Lender that would reasonably be
expected to have or result in a Material Adverse Effect.
j. Absence of
Litigation. There is no
action, suit, proceeding, inquiry or investigation before or by any
court, public board or body pending or, to the knowledge of the
Company, threatened against or affecting the Company before or by
any governmental authority or nongovernmental department,
commission, board, bureau, agency or instrumentality or any other
person, wherein an unfavorable decision, ruling or finding would
have a Material Adverse Effect or which would adversely affect the
validity or enforceability of, or the authority or ability of the
Company to perform its obligations under, any of the Transaction
Agreements. The Company is not aware of any valid basis for any
such claim that (either individually or in the aggregate with all
other such events and circumstances) could reasonably be expected
to have a Material Adverse Effect. There are no outstanding or
unsatisfied judgments, orders, decrees, writs, injunctions or
stipulations to which the Company is a party or by which it or any
of its properties is bound, that involve the transaction
contemplated herein or that, alone or in the aggregate, could
reasonably be expect to have a Material Adverse Effect.
k. Absence of Events of
Default. Except as set
forth in Section 3(e) hereof, (i) neither the Company nor any of
its subsidiaries is in default in the performance or observance of
any material obligation, agreement, covenant or condition contained
in any material indenture, mortgage, deed of trust or other
material agreement to which it is a party or by which its property
is bound, and (ii) no Event of Default (or its equivalent term), as
defined in the respective agreement to which the Company or its
subsidiary is a party, and no event which, with the giving of
notice or the passage of time or both, would become an Event of
Default (or its equivalent term) (as so defined in such agreement),
has occurred and is continuing, which would have a Material Adverse
Effect.
8
l. Absence of Certain Company
Control Person Actions or Events. To the Company’s knowledge, none of the
following has occurred during the past five (5) years with respect
to a Company Control Person:
(1) A petition under the federal
bankruptcy laws or any state insolvency law was filed by or
against, or a receiver, fiscal agent or similar officer was
appointed by a court for the business or property of such Company
Control Person, or any partnership in which he was a general
partner at or within two years before the time of such filing, or
any corporation or business association of which he was an
executive officer at or within two years before the time of such
filing;
(2) Such Company Control Person was
convicted in a criminal proceeding or is a named subject of a
pending criminal proceeding (excluding traffic violations and other
minor offenses);
(3) Such Company Control Person was
the subject of any order, judgment or decree, not subsequently
reversed, suspended or vacated, of any court of competent
jurisdiction, permanently or temporarily enjoining him from, or
otherwise limiting, the following activities:
(i) acting, as an investment
advisor, underwriter, broker or dealer in securities, or as an
affiliated person, director or employee of any investment company,
bank, savings and loan association or insurance company, as a
futures commission merchant, introducing broker, commodity trading
advisor, commodity pool operator, floor broker, any other Person
regulated by the Commodity Futures Trading Commission
(“CFTC”) or engaging in or continuing any conduct or
practice in connection with such activity;
(ii) engaging in any type of
business practice; or
(iii) engaging in any activity in
connection with the purchase or sale of any security or commodity
or in connection with any violation of federal or state securities
laws or federal commodities laws;
(4) Such Company Control Person was
the subject of any order, judgment or decree, not subsequently
reversed, suspended or vacated, of any federal or state authority
barring, suspending or otherwise limiting for more than 60 days the
right of such Company Control Person to engage in any activity
described in paragraph (3) of this item, or to be associated with
Persons engaged in any such activity; or
(5) Such Company Control Person was
found by a court of competent jurisdiction in a civil action or by
the CFTC or SEC to have violated any federal or state securities
law, and the judgment in such civil action or finding by the CFTC
or SEC has not been subsequently reversed, suspended, or
vacated.
9
m. No Undisclosed Liabilities or Events. To
the best of the Company’s knowledge, the Company has no
liabilities or obligations other than those disclosed in the
Transaction Agreements or the Company’s SEC Documents or
those incurred in the ordinary course of the Company’s
business since the Last Audited Date, or which individually or in
the aggregate, do not or would not have a Material Adverse Effect.
No event or circumstances has occurred or exists with respect to
the Company or its properties, business, operations, condition
(financial or otherwise), or results of operations, which, under
applicable law, rule or regulation, requires public disclosure or
announcement prior to the date hereof by the Company but which has
not been so publicly announced or disclosed. There are no proposals
currently under consideration or currently anticipated to be under
consideration by the Board of Directors or the executive officers
of the Company which proposal would (x) change the articles or
certificate of incorporation or other charter document or by-laws
of the Company, each as currently in effect, with or without
shareholder approval, which change would reduce or otherwise
adversely affect the rights and powers of the shareholders of the
Common Stock or (y) materially or substantially change the
business, assets or capital of the Company, including its interests
in subsidiaries.
n. No Integrated
Offering. Neither the
Company nor any of its Affiliates nor any Person acting on its or
their behalf has, directly or indirectly, at any time since March
1, 2004, made any offer or sales of any security or solicited any
offers to buy any security under circumstances that would eliminate
the availability of the exemption from registration under
Regulation D in connection with the offer and sale of the
Securities as contemplated hereby.
o. Confirmation.
The Company confirms that all
statements of the Company contained herein shall survive acceptance
of this Agreement by the Lender. The Company agrees that, if any
events occur or circumstances exist prior to the Closing Date or
the release of the Loan Amount to the Company which would make any
of the Company’s representations, warranties, agreements or
other information set forth herein materially untrue or materially
inaccurate as of such date, the Company shall immediately notify
the Lender (directly or through its counsel, if any) in writing
prior to such date of such fact, specifying which representation,
warranty or covenant is affected and the reasons
therefor.
p. Current Debt with
Lender. The Lender
represents that the current outstanding principal amount of
convertible debentures for Palisades Master Fund, LP is
$9,674,419.50.
4. CERTAIN COVENANTS AND
ACKNOWLEDGMENTS.
a. Transfer
Restrictions. The Lender
acknowledges that (1) the Securities have not been and are not
being registered under the provisions of the 1933 Act and, except
as provided in the Registration Rights Provisions or otherwise
included in an effective registration statement, the Shares have
not been and are not being registered under the 1933 Act, and may
not be transferred unless (A) subsequently registered thereunder or
(B) the Lender shall have delivered to the Company an opinion of
counsel, reasonably satisfactory in form, scope and substance to
the Company, to the effect that the Securities to be sold or
transferred may be sold or transferred pursuant to an exemption
from such registration; (2) any sale of the Securities made in
reliance on Rule 144
10
promulgated under the 1933 Act may be made only
in accordance with the terms of said Rule and further, if said Rule
is not applicable, any resale of such Securities under
circumstances in which the seller, or the Person through whom the
sale is made, may be deemed to be an underwriter, as that term is
used in the 1933 Act, may require compliance with some other
exemption under the 1933 Act or the rules and regulations of the
SEC thereunder; and (3) neither the Company nor any other Person is
under any obligation to register the Securities (other than
pursuant to the Registration Rights Provisions) under the 1933 Act
or to comply with the terms and conditions of any exemption
thereunder.
b. Restrictive Legend.
The Lender acknowledges and agrees
that, until such time as the relevant Shares have been registered
under the 1933 Act, as contemplated by the Registration Rights
Provisions and sold in accordance with an effective Registration
Statement or otherwise in accordance with another effective
registration statement, the certificates and other instruments
representing any of the Securities shall bear a restrictive legend
in substantially the following form (and a stop-transfer order may
be placed against transfer of any such Securities):
THESE SECURITIES HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE
SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR OFFERED FOR
SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES OR AN OPINION OF COUNSEL OR OTHER EVIDENCE ACCEPTABLE TO
THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
c. Filings
. The Company undertakes and agrees
to make all necessary filings in connection with the sale of the
Securities to the Lender under any United States laws and
regulations applicable to the Company, or by any domestic
securities exchange or trading market, and to provide a copy
thereof to the Lender promptly after such filing.
d. Reporting Status
. So long as the Lender
beneficially owns any of the Securities and for at least twenty
(20) Trading Days thereafter, the Company shall file all reports
required to be filed with the SEC pursuant to Section 13 or 15(d)
of the 1934 Act, shall take all reasonable action under its control
to ensure that adequate current public information with respect to
the Company, as required in accordance with Rule 144(c)(2) of the
1933 Act, is publicly available, and shall not terminate its status
as an issuer required to file reports under the 1934 Act even if
the 1934 Act or the rules and regulations thereunder would permit
such termination. The Company will take all reasonable action under
its control to maintain the continued listing and quotation and
trading of its Common Stock (including, without limitation, all
Registrable Securities) on the Principal Trading Market or a
listing on the NASDAQ/Small Cap or National Markets and, to the
extent applicable to it, will comply in all material respects with
the Company’s reporting, filing and other obligations under
the by-laws or rules of the Principal Trading Market and/or the
National Association of Securities Dealers, Inc., as the case may
be, applicable to it at least through the date which is sixty (60)
days after the later of the date on which (x) all of the Notes have
been converted or been paid in full or (y) all of the Warrants have
been exercised or have expired.
11